在中级和高中级风险组的子宫内膜癌患者的淋巴切除术和哨兵淋巴结活检:乌克兰的经验
Olha Khoptiana1, Valentyn Svintsitskyi1, Sergiy Nespryadko1
1Scientific and Clinical Department of the Female Reproductive System Neoplasms, National Cancer Institute, Kyiv, Ukraine.
International journal of women's health
|July 2, 2025
概括
哨兵淋巴结活检是淋巴结切除术的安全替代品,用于子宫内膜癌的分期. 在这两种手术方法中,瘤结果和无复发生存率相似.
科学领域:
- 妇科瘤学 妇科瘤学
- 手术瘤学手术瘤学
- 在瘤学瘤学.
背景情况:
- 子宫内膜癌的分期往往涉及淋巴切除术,这会带来术后并发症的风险.
- 哨兵淋巴结活检 (SLNB) 是一种替代性的手术分期技术.
- 评估SLNB与淋巴切除术之间的瘤安全性和并发症率至关重要.
研究的目的:
- 为了比较SLNB与淋巴切除术在早期子宫内膜腺癌患者的瘤安全性.
- 评估和比较SLNB和淋巴切除术之间的术后并发症率.
主要方法:
- 一个回顾性多中心试验,涉及118名患有中期和高中期I-II期子宫内瘤的患者.
- 患者接受了SLNB (研究组) 或系统性淋巴切除术 (对照组).
- 使用Kaplan-Meier方法分析了无复发生存期;p <0.05被认为是显著的.
主要成果:
- 在SLNB (96.3%) 和淋巴切除术 (89.4%) 之间,无复发生存时间在3年内没有显著差异 (p = 0.608).
- 淋巴管切除组中的6名患者 (5.9%) 出现了复发,其中5名 (4.2%) 死亡.
- 手术后并发症发生在9.3%的30天内和5.9%的90天内.
结论:
- 在精选的子宫内膜癌患者中,SLNB是全身淋巴切除术的可行替代方案,用于手术分期.
- 与传统的淋巴切除术相比,SLNB不会影响无复发的生存率.
- SLNB可能会提供减少的并发症概况,这需要进一步调查.
相关概念视频
Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...


